Pain-relief study for adults with schwannomatosis
Treatments studied
Part of Cancer, Pain clinical trials.
This Phase 2 study tests whether an antibody medicine (either siltuximab or erenumab) can reduce moderate-to-severe pain in adults with schwannomatosis. It compares the medicine to a placebo and looks for improved pain control and tolerability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older at the start of treatment.
- Have a confirmed diagnosis of schwannomatosis (either through clinical findings or genetic test results).
- Have moderate to severe pain from schwannomatosis (pain score 5 or higher out of 10 on the NRS-11) in the last 7 days, and/or at screening.
- Try pain medicines for schwannomatosis first, but they must not have worked enough, not have been tolerated, or not be safe for you to use.
- Have recent blood tests within required ranges for liver, kidneys, blood counts, and other markers (done within 28 days of starting).
- Be able to give informed consent and follow study visits; you must also have a primary care contact.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It first tracks the natural course of the disease and may later test experimental drugs to help shrink or control tumors.
This trial tests a new injection called sss40 to treat moderate-to-severe pain caused by cancer that has spread to the bones. The goal is to see if it is safe and effective for people whose pain is not being controlled by current treatments.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This study tests a new medicine called efgartigimod to see if it can help people with Sjogren's disease who have nerve damage (neuropathy). You may be able to join if your nerve symptoms started within the last 5 years and are getting worse.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Hear when a new Schwannomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.